UNSPSC 51271914: Propoxycaine

This classification denotes an anesthetic agent with the molecular formula C16H26N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EPD1EH7F53, chemically known as 4-amino-2-propoxybenzoic acid, 2-(diethylamino)ethyl ester but generally known as propoxycaine, which bears US NIH Compound Identifier 6843. European Medicines Agency schedules Propoxycaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10118MIG.

UNSPSC 51271914 Propoxycaine, a Commodity code, covers local anesthetic pharmaceuticals sourced through state and local cooperative purchasing agreements and direct government procurement. State and local agencies buy propoxycaine primarily as a component of broader generic pharmaceutical and over-the-counter product contracts negotiated through multistate cooperative purchasing alliances. The issuing bodies are state procurement offices administering cooperative purchasing vehicles on behalf of multiple participating state and local government facilities, including departments of administration, health departments, and institutional healthcare operations. Work under this code involves supplying pharmaceutical manufacturers' products to authorized wholesalers and downstream government healthcare facilities, with vendors required to maintain cGMP certification, Drug Supply Chain Security Act compliance, contractual relationships with specified pharmaceutical distributors, and comprehensive insurance coverage including commercial general liability and professional liability policies.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued the most recent visible opportunity under this code: an RFP (S1070000015802) posted January 20, 2026, for a multi-source pharmaceutical and OTC product contract with a March 26, 2026 proposal deadline. The RFP seeks manufacturers to supply generic pharmaceuticals including propoxycaine through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with products available by May 15, 2026 and contracts effective July 1, 2026. Evaluation is weighted heavily toward price competitiveness (75 percent), with secondary emphasis on fixed pricing (10 percent) and compliance with EDI capability, administrative fee data format, and chargeback system requirements. The contract term is two years for new responders with optional extensions, and MMCAP retains discretion to make sole, dual, or multi-awards based on therapeutic and patient safety considerations. Geographic activity centers on Minnesota and participating states including Oregon, with distribution through a national pharmaceutical wholesale network.